Fcγ-receptor-activation by circulating immune complexes in systemic autoimmune diseases and its reduction by CD19-CAR T cell therapy
Authors' conclusion
Our study reveals the presence of FcγR-engaging cICs in CTDs and demonstrates that the bioactivity of cICs is correlated with clinical phenotypes and treatment outcomes.
Study context
- Population
- IgG-autoantibody-positive connective tissue diseases (CTD) patients, and CTD patients treated with CD19-CAR T cells
- Comparison
- IgG-autoantibody-positive CTD vs healthy controls and IgG-autoantibody-negative systemic inflammatory disease (PsA); CTD before vs after CD19-CAR T cell therapy
- Outcome
- Bioactivity (FcγR activation) of IgG-containing cICs
Methodological detailscross-sectional analysis, longitudinal analysis, reporter cell platform
- Cross-sectional analysis
- Longitudinal analysis
- Reporter cell platform
Main finding
As reported in the abstract
cIC bioactivity
- cIC bioactivity significantly higher in CTD vs healthy controls and PsA
- Circulating immune complexes (cICs) present in sera of all CTDs, incl. Systemic sclerosis (SSc) and primary Sjögren's syndrome, with significant heterogeneity among individuals
- cIC bioactivity significantly reduced in CTD patients after CD19-CAR T cell therapy
Further findings
cIC bioactivity within SSc
- Significantly enhanced cIC bioactivity in anti-topoisomerase-I (Scl70)-positive, diffuse cutaneous and lung involvement
Original publication
Fcγ-receptor-activation by circulating immune complexes in systemic autoimmune diseases and its reduction by CD19-CAR T cell therapy. Rheumatology (Oxford). Published 3 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →